Is streptokinase useful in the treatment of deep vein thrombosis?
| Autor: | Robert Bieger, E. A. Loeliger, Frits Hohmann, Ria J. Boekhout-Mussert |
|---|---|
| Rok vydání: | 1976 |
| Předmět: |
Adult
Male medicine.medical_specialty Streptokinase Deep vein Phenprocoumon Popliteal vein Internal Medicine Medicine Humans Prospective Studies Prospective cohort study Vein Retrospective Studies business.industry Heparin Thrombin Fibrinogen Middle Aged Thrombophlebitis medicine.disease Thrombosis Surgery medicine.anatomical_structure Female business medicine.drug Follow-Up Studies |
| Zdroj: | Acta medica Scandinavica. 199(1-2) |
| ISSN: | 0001-6101 |
| Popis: | Because of its fibrinolytic action, streptokinase is believed to reduce the severity of the postthrombotic syndrome in patients with deep vein thrombosis. A prospective and a retrospective study have been undertaken in an attempt to determine when this therapy is useful for patients with deep vein thrombosis. The prospective study included 15 patients with deep vein thrombosis: 5 were treated in the hospital with streptokinase and heparin and 5 only with heparin, 5 were treated at home with only phenprocoumon. Ail the patients received oral anticoagulant therapy for at least 6 months. Three to four months after the acute episode, phlebography and venous pressure measurements were carried out. Streptokinase appeared to give the best results but with more side-effects. In the retrospective study, 51 patients who had had deep vein thrombosis in 1969 were reexamined 31–47 months later. It was found that more than 50 % of the patients with a thrombosis in the femoral and/or iliac vein developed a severe postthrombotic syndrome, in contrast to only 9% of those with a thrombosis in the popliteal vein or lower. It is recommended, on the basis of both the prospective and the retrospective study, that patients with a thrombosis in the femoral and/or iliac vein should be treated with either heparin or streptokinase during the early stage. It is probable that streptokinase will significantly decrease the frequency and severity of the postthrombotic syndrome in these patients in particular, although this has not yet been proven. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text